InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,528.93
(
-2.12%
)
US TECH 100
18,438.40
(
-3.21%
)
Dow Jones
40,936.93
(
-1.51%
)
Brent Oil
73.65
(
-4.59%
)
Bitcoin
58,094.53
(
-1.74%
)
Post# of 253030
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 837
Posts 120361
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: drbio45 post# 141226

Thursday, 05/03/2012 6:48:38 PM

Thursday, May 03, 2012 6:48:38 PM

Post# of 253030
If you’re attending ARVO, you can see OHRP’s poster on Squalamine eye drops:

http://finance.yahoo.com/news/ohr-pharmaceutical-present-arvo-annual-123000769.html

Abstract title: “A Novel Eye Drop Formulation of Squalamine For Exudative AMD: Evaluation Of Ocular Distribution And Ocular Safety In Rabbits”

Recap: Ten years after this drug was first tested in human eyes, we have a distribution and safety study in rabbits!

I’m willing to bet that this program won’t work for the reason mentioned in #msg-75138549.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up